The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2017 | What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
Paul Richardson, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the use of ixazomib in the treatment of multiple myeloma at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He describes results from the randomized placebo-controlled Phase III TOURMALINE-MM2 trial (NCT01850524) of this oral proteasome inhibitor, including efficacy, tolerability and safety. Prof. Richardson also speaks about results from subgroup analyses which revealed good efficacy in pre-treated patients with high-risk cytogenetics.
